BioBlast Pharma Ltd., a clinical-stage biotechnology company developing therapies for patients with rare and ultra-rare genetic diseases, has appointed Theresa Stevens to the newly-created position of chief corporate development officer (CCDO). Ms. Stevens will be a member of BioBlast’s executive committee and will oversee, in particular, the corporate strategy, M&A, and business development of marketed and development stage in- and out-licensing. “I’m thrilled to have T...